|1.||Schally, Andrew V: 12 articles (01/2011 - 10/2003)|
|2.||Halmos, Gabor: 9 articles (07/2006 - 10/2003)|
|3.||Nagy, Attila: 9 articles (01/2006 - 10/2003)|
|4.||Keller, Gunhild: 5 articles (07/2006 - 03/2005)|
|5.||Baker, Benjamin: 4 articles (07/2006 - 08/2005)|
|6.||Engel, Jörg B: 4 articles (07/2006 - 03/2005)|
|7.||Szepeshazi, Karoly: 3 articles (01/2006 - 10/2003)|
|8.||Engel, Jorg B: 2 articles (01/2011 - 11/2005)|
|9.||Kanashiro, Celia A: 2 articles (01/2006 - 07/2005)|
|10.||Nagy, A: 2 articles (04/2002 - 11/2000)|
|1.||Glioblastoma (Glioblastoma Multiforme)
04/22/2002 - "This study reports the effect of AN-215 on the growth of U-87MG human glioblastomas xenografted into nude mice. "
04/22/2002 - "Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215."
07/01/2005 - "Our results suggest that targeted cytotoxic analogs, AN-215 and AN-238, could be useful for the treatment of human glioblastomas."
07/01/2005 - "In the present study, the efficacy and the mechanism of action of cytotoxic bombesin analog AN-215, and cytotoxic somatostatin analog AN-238 were investigated in U-118MG human glioblastomas xenografted into nude mice. "
04/22/2002 - "We investigated whether bombesin/gastrin releasing peptide receptors found in glioblastoma cell lines can be utilised for targeting of a cytotoxic bombesin analogue, AN-215 consisting of a potent derivative of doxorubicin, 2-pyrrolino-doxorubicin (AN-201) linked to a bombesin-like peptide carrier. "
|2.||Endometrial Neoplasms (Endometrial Cancer)
08/01/2005 - "Thus, targeted chemotherapy with AN-215 powerfully inhibits the growth of human BN receptor-positive endometrial cancers."
08/01/2005 - "In this study we have investigated the efficacy and toxicity of targeted cytotoxic bombesin (BN) analog AN-215 and its effects on the expression of three multidrug resistance proteins in experimental human endometrial cancers. "
08/01/2005 - "Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins."
03/15/2005 - "AN-215 significantly (P < 0.05) inhibited growth of ES-2, OV-1063, and UCI-107 tumors, prevented the metastatic spread of ES-2 cancers, and prolonged the survival of nude mice bearing i.p. "
11/15/2000 - "Administration of 200 nmol/kg AN-215 on days 1, 7, 17 and 26 again produced 69% tumor inhibition. "
11/15/2000 - "After treatment with AN-215, tumor volume was 69% (p < 0.01) smaller than that in controls and tumor doubling time was extended from 8.5 +/- 0.7 days to 20.3 +/- 3.5 days (p < 0.05). "
07/05/2006 - "AN-215 alone at 200 nmol/kg and its combination with AN-238 at one-half of the dose were also able to inhibit the growth of UCI-107 tumors. "
01/01/2006 - "Therapy with AN-215, but not with AN-201, decreased the ratio of Bcl-2/Bax in DU-145 and the expression of antiapoptotic Bcl-2 in LuCaP-35 tumors. "
|4.||Prostatic Neoplasms (Prostate Cancer)
01/01/2006 - "The presence of BN/GRP receptors on primary and metastatic prostate cancers makes possible targeted chemotherapy with AN-215 for the treatment of this malignancy."
10/15/2010 - "These findings shed light on the mechanisms of action of these analogs and support the view that the use of AN-215 and RC-3095 for blocking BN/GRP receptors for targeted therapy may be of benefit for treatment of advanced prostate cancer."
01/01/2006 - "Targeted analog AN-215 significantly inhibited growth of subcutaneously implanted DU-145, LuCaP-35 and MDA-PCa-2b prostate cancers by 81% to 91% compared to controls, while cytotoxic radical AN-201 was less effective and more toxic. "
01/01/2006 - "The effects of targeted chemotherapy with cytotoxic BN analogue AN-215 were evaluated in nude mice bearing subcutaneous xenografts of DU-145, LuCaP-35, MDA-PCa-2b and intraosseous implants of C4-2 human prostate cancers. "
11/15/2000 - "In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215."
03/15/2005 - "AN-215 might provide a new treatment modality for women with advanced ovarian carcinoma."
03/15/2005 - "Nude mice bearing xenografts of ES-2, SKOV-3, OV-1063, and UCI-107 human ovarian carcinomas were treated with AN-215. "
12/01/2005 - "In conclusion, targeted chemotherapy with the cytotoxic BN/GRP analog AN-215 strongly inhibits breast cancers that express BN/GRP receptors and might provide a new treatment modality for mammary carcinoma."
10/01/2005 - "Bombesin/GRP receptors are expressed on most ductal pancreatic carcinoma cell lines and can be used for targeted chemotherapy with the cytotoxic bombesin analog AN-215."
11/15/2000 - "AN-215 showed a high affinity to PC-3 tumors, displacing the radioligand at an IC(50) of 12.95 +/- 0.35 nM. Because BN receptors are present on primary and metastatic prostate cancer, targeted chemotherapy with AN-215 might benefit patients with advanced prostatic carcinoma who relapsed androgen ablation."
|3.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|5.||AN 204 (AN 201)
|7.||Bombesin Receptors (Bombesin Receptor)
|9.||Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Investigational Therapies (Experimental Therapy)